Project Grant R21AI193559
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$424K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to define the importance of riboflavin synthesis and transport to the survival of Mycobacterium tuberculosis (MTB) during infection. The $231,000 award to the Regents of the University of Minnesota will be used to determine if MTB requires de novo riboflavin synthesis for replication and survival in host...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $721,194 to Florida State University to conduct research on the cell division process of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The key objectives are to: (1) investigate the structural and functional roles of the FtsQ-FtsZ protein interaction; (2) characterize the structure,...
This Project Grant award of $176,152, provided by the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify new drug targets against drug-tolerant strains of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The research aims to study the role of lipid metabolism and host-pathogen interactions in conferring drug tolerance to MTB strains with deficient glycerol...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award of $265,650 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop novel medicinal chemistry strategies to overcome multidrug-resistant tuberculosis (MDR-TB) and rifampicin-resistant TB (RR-TB). The research aims to establish the structure-activity relationship and mechanism of action of modified rifabutin analogs that demonstrate enhanced potency against...
This Project Grant award of $162,000.00 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize the role of plasmacytoid dendritic cells (pDCs) in Mycobacterium tuberculosis (MTB) infection. The goal is to identify pDC-specific therapeutic targets that could lead to host-directed therapies for tuberculosis. The 2-year project, running from Jun 1, 2025 to May 31, 2027, will leverage advanced...
This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $130,776 to Lake Forest College to characterize the role of the mycobacterial BrkB ortholog in the pathogenesis of tuberculosis (TB). The project aims to identify the biochemical function and substrates of the BrkB protein, determine its mechanism for requiring extracellular growth, and measure its role under...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $749,414 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University for research on the role of macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis. The primary objectives are to: 1) define the role of MDR1 in M.TB survival in macrophages; 2) determine if HSF1 activation or MDR1 inhibition can shorten M.TB sterilization by TB drugs;...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $565,149 to Health Research, Inc. Wadsworth Center Division to conduct research on RNA-based regulatory mechanisms in Mycobacterium tuberculosis (MTB). The primary objectives are to: Define the regulatory interactions of the sRNA MCR11 and its impact on gene expression in MTB. Characterize the roles of RNA-ABMR...